Albert David Limited, a prominent pharmaceutical company, has reported a significant drop in its net profit for the first quarter of the fiscal year. The company's financial performance and recent board decisions have brought attention to its operations and governance.

Financial Performance

Albert David's net profit for Q1 declined sharply to ₹77.50 million, compared to ₹190.40 million in the same quarter of the previous year. This represents a substantial year-over-year decline of 59.30%, indicating challenging market conditions or increased operational costs for the company.

Board Meeting Outcomes

The company's Board of Directors convened on August 2, and made several important decisions:

1. Financial Results Approval: The Board considered and approved the Unaudited Financial Results for the first quarter ended June 30. These results, along with the Limited Review Report from the auditors, will be published in newspapers as per regulatory requirements.

2. Appointment of New Independent Director: Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of Dr. Rajiv Anant Desai (DIN: 11193975) as an Additional Non-Executive Independent Director of the company. Dr. Desai's appointment is effective from August 2, for a period of five consecutive years, subject to shareholder approval through a postal ballot.

New Independent Director Profile

Dr. Rajiv Anant Desai brings a wealth of experience to Albert David Limited:

• Educational Background: M.Sc. in Chemistry from Mumbai University, Ph.D. in Pharmaceutical Chemistry from ICT Mumbai, and MBA from NMIMS, Mumbai.
• Professional Experience: Over 38 years of experience in the pharmaceutical industry across various geographies.
• Current Roles: Senior Technical Advisor-Quality and Regulatory with Indian Pharmaceutical Alliance (IPA) since July 2022, and freelance consultant and advisor for the pharmaceutical industry.
• Previous Position: Executive Vice President, Global Corporate Quality at Lupin Limited from June 2016 to June 2022.
• Industry Contributions: Former member of the US Pharmacopeia Expert Committee and current member of the Indian Pharmacopoeia Expert committee.
• Academic Involvement: Visiting faculty at several prestigious institutions and member of Board of Studies at multiple colleges in Mumbai for syllabus setting and Ph.D. research.

Dr. Desai's appointment is expected to bring valuable insights and expertise to Albert David's board, potentially contributing to the company's strategic direction and quality management initiatives.

The board meeting, which started at 12:00 P.M. and concluded at 16:40 P.M., also approved the Postal Ballot Notice for obtaining shareholders' approval for Dr. Desai's appointment.

As Albert David navigates through the challenges reflected in its Q1 results, the addition of Dr. Desai to its board signals the company's commitment to strengthening its governance and leveraging industry expertise to improve its performance in the coming quarters.

Albert David Ltd , a pharmaceutical company, has released its financial results for the fourth quarter of the fiscal year 2023. The company's performance shows mixed results with improvements in some areas but challenges in others. Additionally, the company has announced a dividend recommendation.

Financial Highlights

Key Points

• Revenue decreased by 15.94% year-on-year
• EBITDA swung from a profit to a loss
• Net loss improved by 20.16% compared to Q4 FY22
• Net loss increased from ₹94.00 crore in Q3 FY23 to ₹103.00 crore in Q4 FY23
• Dividend of ₹5 per equity share recommended

Revenue Decline

Albert David Ltd experienced a significant year-on-year decline in revenue for the fourth quarter. The company's revenue stood at ₹749.00 crore, marking a decrease from ₹891.00 crore reported in the same quarter of the previous fiscal year. This represents a decline of 15.94% in top-line performance.

EBITDA Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) took a substantial hit in Q4 FY23. Albert David Ltd reported an EBITDA loss of ₹48.00 crore, a stark contrast to the EBITDA gain of ₹96.00 crore in the corresponding quarter of the previous year. This swing indicates significant pressure on the company's operational efficiency and profitability.

Bottom Line Improvement

Despite the challenges in revenue and EBITDA, Albert David Ltd showed some improvement in its bottom line. The net loss for Q4 FY23 stood at ₹103.00 crore, which is an improvement from the ₹129.00 crore loss reported in the same quarter of the previous year. This represents a reduction in net loss by 20.16% year-on-year.

Sequential Performance

When compared to the previous quarter (Q3 FY23), the company's performance showed a slight deterioration. The net loss increased from ₹94.00 crore in Q3 FY23 to ₹103.00 crore in Q4 FY23, indicating ongoing challenges in the company's financial performance.

Dividend Announcement

In a positive development for shareholders, Albert David Ltd has announced a recommendation for a dividend of ₹5 per equity share. This decision demonstrates the company's commitment to returning value to its shareholders despite the challenging financial results.

Conclusion

The pharmaceutical sector has been facing various challenges, including pricing pressures and regulatory changes. Albert David Ltd's mixed results reflect these industry-wide trends, with improvements in some areas offset by declines in others. The company's management will likely focus on strategies to boost revenue and operational efficiency in the coming quarters to address the EBITDA loss and improve overall financial performance. The dividend recommendation, however, provides some reassurance to investors about the company's financial stability and shareholder-friendly approach.